Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study

Leuk Lymphoma. 2004 Aug;45(8):1627-31. doi: 10.1080/10428190410001683732.


Following therapy with imatinib (STI571) hematologic and cytogenetic response in chronic myeloid leukemia (CML) is associated with conspicuous alterations of bone marrow (BM) morphology. Besides reduction of cellularity and fibrosis, small megakaryocytes characteristic for this disorder were replaced by large, normally appearing cells of this lineage. However, it is not known whether and to which extent these changes are accompanied by a loss of the bcr/abl translocation. Therefore an immunohistochemical (CD61) and fluorescence in-situ hybridization (FISH) study was performed on sequential BM biopsies in 5 patients with CML receiving STI571 without any pretreatment. Morphometric analysis revealed that the prevalent population of 47% micromegakaryocytes (size < or = 150 microm2) was significantly reduced (15%) during therapy and that a conspicuous shift to medium-sized and large megakaryocytes occurred. According to FISH analysis in the initial BM biopsy sections 71% of all myeloid cells exhibited the bcr/abl gene and concerning megakaryopoiesis about 65% of the prominent micromegakaryocytes displayed positive signals. After treatment this peculiar cell population decreased significantly while the emerging large megakaryocytes (52%) totally lacked a bcr/abl labeling. Because cytogenetic response and reduction of micromegakaryocytes seem to be linked, this feature may be useful to monitor therapeutic efficacy by evaluating BM morphology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Biopsy
  • Bone Marrow / pathology
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • In Situ Hybridization, Fluorescence / methods
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Megakaryocytes / pathology*
  • Piperazines / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / therapeutic use*
  • Translocation, Genetic*


  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl